In vitro and in vivo efficacy of tecovirimat against a recently emerged 2022 monkeypox virus isolate

The recent emergence of the monkeypox virus (MPXV) in non-endemic countries has been designated a Public Health Emergency of International Concern by the World Health Organization. There are currently no approved treatments for MPXV infection in the United States or Canada. The antiviral drug tecovi...

Full description

Saved in:
Bibliographic Details
Published in:Science translational medicine 2022-11, Vol.14 (673), p.eade7646-eade7646
Main Authors: Warner, Bryce M, Klassen, Levi, Sloan, Angela, Deschambault, Yvon, Soule, Geoff, Banadyga, Logan, Cao, Jingxin, Strong, James E, Kobasa, Darwyn, Safronetz, David
Format: Article
Language:English
Subjects:
Animals
Canada
Infections
Isoindoles - pharmacology
Isoindoles - therapeutic use
Mice
Monkeypox virus
Mpox
Mpox (monkeypox) - drug therapy
Mpox (monkeypox) - prevention & control
Outbreaks
Public health
Respiratory tract diseases
Smallpox
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The recent emergence of the monkeypox virus (MPXV) in non-endemic countries has been designated a Public Health Emergency of International Concern by the World Health Organization. There are currently no approved treatments for MPXV infection in the United States or Canada. The antiviral drug tecovirimat (commonly called TPOXX), previously approved for smallpox treatment, is currently being deployed for treatment of MPXV infections where available based on previously accrued data. We tested the efficacy of TPOXX both in vitro and in vivo against a clade 2 Canadian 2022 isolate of MPXV isolated during the current outbreak. TPOXX prevented MPXV replication in vitro with an effective concentration in the nanomolar range. To evaluate TPOXX efficacy in vivo, we first characterized the CAST/EiJ mouse model with the same 2022 Canadian isolate. Unlike previous descriptions of this model, the Canadian isolate was not lethal in CAST/EiJ mice, although it replicated efficiently in the respiratory tract after intranasal infection. Subsequent experiments demonstrated that daily oral TPOXX treatment markedly reduced viral titers in the tissues 1 and 2 weeks after infection. Our data indicate that TPOXX is highly effective against currently circulating MPXV strains and could be an important contributor to curbing the ongoing outbreak.
ISSN:1946-6234
1946-6242
1946-3242
DOI:10.1126/scitranslmed.ade7646